Addex Extends Its Runway With CHF 20 Million Investment By BVF
This article was originally published in The Pink Sheet Daily
Executive Summary
Last year's failure of GERD candidate ADX10059 enabled BVF to buy in at a value price, but Addex won't make mistake of focusing primarily on one asset again.
You may also be interested in...
Financings Of The Fortnight: Crossover Investors Key To Intarcia’s Massive $210 Million Series C Round
Plus news on recent financings by Visterra, AbbVie, Pearl Therapeutics and Auspex.
Addex Wins Michael J. Fox Foundation Funding To Take Its Dopamine Side Effect Therapy Into Phase II Testing
After a costly 2009 setback, venture philanthropy steps in to help Addex move a risky program forward.
Scrappy Addex Has A Plan For Reviving Faith In Its Allosteric Modulators
With 15 programs in various stages of early development, the Swiss biotech ratchets up the emphasis on partnering to gain back support and non-dilutive capital after the failure of its lead compound.